Brenner, Bluma GThomas, RejeanBlanco, Jose LuisIbanescu, Ruxandra-IlincaOliveira, MaureenMesplede, ThibaultGolubkov, OlgaRoger, MichelGarcia, FedericoMartinez, EstebanWainberg, Mark A2023-01-252023-01-252016-02-17Brenner BG, Thomas R, Blanco JL, Ibanescu RI, Oliveira M, Mesplède T, et al. Development of a G118R mutation in HIV-1 integrase following a switch to dolutegravir monotherapy leading to cross-resistance to integrase inhibitors. J Antimicrob Chemother. 2016 Jul;71(7):1948-53.http://hdl.handle.net/10668/9956Dolutegravir shows a high barrier to resistance with no previously reported cases of acquired integrase mutations during first-line therapy. In this study, rapid development of the G118R mutation arose following a switch from first-line elvitegravir/cobicistat/tenofovir disoproxil fumarate/emtricitabine to dolutegravir monotherapy. The G118R mutation also arose in a treatment-experienced patient switched to dolutegravir monotherapy. The genetic basis for G118R selection and potential phenotypic outcome was ascertained. Genotypic analysis was performed on patients with virological failure ( We report on two patients who developed viral failure while on dolutegravir monotherapy. Both patients had been on a current or previous regimen containing integrase inhibitors. Virological failure ( Although resistance to dolutegravir is typically rare, genetic polymorphisms and monotherapy can facilitate the acquisition of G118R.enHIV Integrase InhibitorsHeterocyclic Compounds, 3-RingOxazinesPiperazinesPyridonesAdultDrug Resistance, ViralGenotyping TechniquesHIV InfectionsHIV IntegraseHIV Integrase InhibitorsHIV-1Heterocyclic Compounds, 3-RingHumansMaleMicrobial Sensitivity TestsMiddle AgedMutation, MissenseOxazinesPiperazinesPyridonesTreatment FailureDevelopment of a G118R mutation in HIV-1 integrase following a switch to dolutegravir monotherapy leading to cross-resistance to integrase inhibitors.research article27029845open accessCompuestos heterocĂclicos con 3 anillosFarmacorresistencia viralInfecciones por VIHInhibidores de integrasa VIHIntegrasa de VIH10.1093/jac/dkw0711460-2091PMC4896408https://academic.oup.com/jac/article-pdf/71/7/1948/11281997/dkw071.pdfhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4896408/pdf